ATE158282T1 - Kondensierte benzeoxyessigsäurederivate - Google Patents

Kondensierte benzeoxyessigsäurederivate

Info

Publication number: ATE158282T1
Authority: AT; Austria
Prior art keywords: chem; alkyl; benzeoxyacetic; condensed; acid derivatives
Prior art date: 1991-12-27

Application number

AT92121898T

Other languages

English (en)

Inventor

Nobuyuki Hamanaka

Kanji Takahashi

Hidekado Tokumoto

Original Assignee

Ono Pharmaceutical Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-12-27

Filing date

1992-12-23

Publication date

1997-10-15

1991-12-27 Priority claimed from JP3360502A external-priority patent/JPH05178832A/ja

1992-07-14 Priority claimed from JP4209587A external-priority patent/JPH0725854A/ja

1992-12-23 Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co

1997-10-15 Application granted granted Critical

1997-10-15 Publication of ATE158282T1 publication Critical patent/ATE158282T1/de

Links

239000002253 acid Substances 0.000 title 1
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 3
125000000217 alkyl group Chemical group 0.000 abstract 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 3
125000003545 alkoxy group Chemical group 0.000 abstract 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
206010003210 Arteriosclerosis Diseases 0.000 abstract 1
102000009079 Epoprostenol Receptors Human genes 0.000 abstract 1
108010073099 Epoprostenol Receptors Proteins 0.000 abstract 1
WZELXJBMMZFDDU-UHFFFAOYSA-N Imidazol-2-one Chemical compound O=C1N=CC=N1 WZELXJBMMZFDDU-UHFFFAOYSA-N 0.000 abstract 1
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 abstract 1
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 abstract 1
208000007536 Thrombosis Diseases 0.000 abstract 1
230000001270 agonistic effect Effects 0.000 abstract 1
150000001413 amino acids Chemical class 0.000 abstract 1
208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
230000002496 gastric effect Effects 0.000 abstract 1
229910052736 halogen Inorganic materials 0.000 abstract 1
150000002367 halogens Chemical class 0.000 abstract 1
208000019622 heart disease Diseases 0.000 abstract 1
-1 imidazole-2-yloxy(thio) Chemical class 0.000 abstract 1
ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 abstract 1
CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 abstract 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 abstract 1
LCPDWSOZIOUXRV-UHFFFAOYSA-N phenoxyacetic acid Chemical class OC(=O)COC1=CC=CC=C1 LCPDWSOZIOUXRV-UHFFFAOYSA-N 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
150000003852 triazoles Chemical class 0.000 abstract 1
125000004953 trihalomethyl group Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Thiazole And Isothizaole Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

AT92121898T 1991-12-27 1992-12-23 Kondensierte benzeoxyessigsäurederivate ATE158282T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP3360502A JPH05178832A (ja)	1991-12-27	1991-12-27	縮合ベンゼンオキシ酢酸誘導体
JP4209587A JPH0725854A (ja)	1992-07-14	1992-07-14	縮合ベンゼンオキシ酢酸誘導体

Publications (1)

Publication Number	Publication Date
ATE158282T1 true ATE158282T1 (de)	1997-10-15

Family

ID=26517547

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT92121898T ATE158282T1 (de)	1991-12-27	1992-12-23	Kondensierte benzeoxyessigsäurederivate

Country Status (11)

Country	Link
US (4)	US5389666A (de)
EP (1)	EP0548949B1 (de)
JP (1)	JP3419009B2 (de)
KR (1)	KR0148389B1 (de)
AT (1)	ATE158282T1 (de)
CA (1)	CA2085844A1 (de)
DE (1)	DE69222280T2 (de)
DK (1)	DK0548949T5 (de)
ES (1)	ES2108076T3 (de)
GR (1)	GR3024771T3 (de)
TW (1)	TW221291B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2085844A1 (en) *	1991-12-27	1993-06-28	Nobuyuki Hamanaka	Fused benzeneoxyacetic acid derivatives
DE4330959A1 (de) *	1993-09-09	1995-03-16	Schering Ag	Neue Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
IT1265209B1 (it) *	1993-11-22	1996-10-31	Pierrel Spa	Difenilimidazoli utili nel trattamento di dislipidemia, arteriosclerosi e malattie coronariche procedimento per la loro
EP0799189A4 (de) *	1994-12-13	1999-03-17	Smithkline Beecham Corp	Bicyclische fibrinogen-antagonisten
KR100436812B1 (ko) *	1995-01-06	2004-08-31	도레이 가부시끼가이샤	벤젠축합헤테로환유도체및그유도체를유효성분으로함유하는의약조성물
CN1202084C (zh) *	1998-08-04	2005-05-18	东丽株式会社	苯稠合杂环衍生物及其用途
US6781288B2 (en) *	1999-01-27	2004-08-24	Bae Systems Information And Electronic Systems Integration Inc.	Ultra-low frequency acoustic transducer
CA2377593A1 (en) *	1999-06-21	2000-12-28	Fujisawa Pharmaceutical Co., Ltd.	Remedies for skin ulcer
JP2001131151A (ja) *	1999-11-02	2001-05-15	Shionogi & Co Ltd	オレフィン誘導体の新規用途
US8124625B2 (en)	2001-09-14	2012-02-28	Shionogi & Co., Ltd.	Method of enhancing the expression of apolipoprotein AI using olefin derivatives
DK1482931T3 (da) *	2002-03-05	2011-12-19	Transtech Pharma Inc	Mono- og bicycliske azolderivater der inhiberer interaktionen af ligander med RAGE
FR2846328B1 (fr) *	2002-10-23	2004-12-10	Servier Lab	Nouveaux derives de l'imidazoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
WO2005000295A1 (en) *	2003-05-20	2005-01-06	Transtech Pharma, Inc.	Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
WO2009117095A1 (en) *	2008-03-18	2009-09-24	Arena Pharmaceuticals, Inc.	Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
US20110224262A1 (en)	2008-11-26	2011-09-15	Arena Pharmaceuticals, Inc.	Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
ES2548882T3 (es)	2008-12-08	2015-10-21	Arena Pharmaceuticals, Inc.	Moduladores del receptor de prostaciclina (PGl2) útiles para el tratamiento de trastornos relacionados con los mismos
JP5805646B2 (ja)	2009-09-30	2015-11-04	ブイティーブイ・セラピューティクス・エルエルシー	アルツハイマー病の治療のための置換イミダゾール誘導体
US10537546B2 (en)	2014-10-23	2020-01-21	Arena Pharmaceuticals, Inc.	Method of treating conditions related to the PGI2 receptor
US12377067B2 (en)	2016-11-10	2025-08-05	Arena Pharmaceuticals, Inc.	Methods of treating PAH with combinations of ralinepag and other agents
IL268997B2 (en)	2017-03-01	2023-09-01	Arena Pharm Inc	Preparations containing pgi2 receptor agonists and processes for their preparation
EP3796902A1 (de)	2018-05-16	2021-03-31	Arena Pharmaceuticals, Inc.	Zusammensetzungen mit pgi2-rezeptoragonisten und verfahren zu deren herstellung
WO2023158634A1 (en)	2022-02-15	2023-08-24	United Therapeutics Corporation	Crystalline prostacyclin (ip) receptor agonist and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1108619A (en) *	1977-08-12	1981-09-08	Carl H. Ross	4-hydroxy-2-benzimidazolinone derivatives and the preparation thereof
EP0045118B1 (de) *	1979-01-05	1984-04-04	National Research Development Corporation	Zwischenprodukte für die Synthese von Bizyklo(2,2,1)heptanen und Bizyklo(2,2,1)hept-2Z-enen
ZA814307B (en) *	1980-07-01	1983-02-23	Nat Res Dev	Prostaglandins
DE3042466A1 (de) *	1980-11-11	1982-06-16	A. Nattermann & Cie GmbH, 5000 Köln	N-substituierte (omega) -(2-oxo-4-imidazolin-l-yl)-alkansaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
FR2498382A1 (fr) *	1981-01-16	1982-07-23	Commissariat Energie Atomique	Connecteur electrique
JPS57150667A (en) *	1981-02-12	1982-09-17	Wellcome Found	Antithrombotic
US4492708A (en) *	1982-09-27	1985-01-08	Eli Lilly And Company	Antiviral benzimidazoles
DE3504677A1 (de) *	1985-02-12	1986-08-14	A. Nattermann & Cie GmbH, 5000 Köln	Neue imidazol-2-yloxyalkansaeuren und ihre derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
CA2003283A1 (en) *	1988-12-05	1990-06-05	C. Anne Higley	Imidazoles for the treatment of atherosclerosis
US4956379A (en) *	1990-02-13	1990-09-11	Bristol-Myers Squibb Company	Pyrazole carboxylic acids and esters and inhibition of blood platelet aggregation therewith
US5011851A (en) *	1990-02-13	1991-04-30	Bristol-Myers Squibb Co.	Imidazole carboxylic acids and esters and inhibition of blood platelet aggregation therewith
EP0442448A3 (en) *	1990-02-13	1992-08-12	Bristol-Myers Squibb Company	Heterocyclic carboxylic acids and esters
CA2085844A1 (en) *	1991-12-27	1993-06-28	Nobuyuki Hamanaka	Fused benzeneoxyacetic acid derivatives
JP2556418B2 (ja) *	1992-07-14	1996-11-20	大光炉材株式会社	不定形耐火材

1992
- 1992-12-18 CA CA002085844A patent/CA2085844A1/en not_active Abandoned
- 1992-12-22 TW TW081110276A patent/TW221291B/zh active
- 1992-12-23 DK DK92121898T patent/DK0548949T5/da active
- 1992-12-23 ES ES92121898T patent/ES2108076T3/es not_active Expired - Lifetime
- 1992-12-23 EP EP92121898A patent/EP0548949B1/de not_active Expired - Lifetime
- 1992-12-23 DE DE69222280T patent/DE69222280T2/de not_active Expired - Fee Related
- 1992-12-23 AT AT92121898T patent/ATE158282T1/de not_active IP Right Cessation
- 1992-12-28 US US07/997,492 patent/US5389666A/en not_active Expired - Fee Related
- 1992-12-28 JP JP36060892A patent/JP3419009B2/ja not_active Expired - Fee Related
- 1992-12-28 KR KR1019920025744A patent/KR0148389B1/ko not_active Expired - Fee Related
1994
- 1994-11-03 US US08/334,395 patent/US5589496A/en not_active Expired - Fee Related
1996
- 1996-09-27 US US08/722,456 patent/US5849919A/en not_active Expired - Fee Related
1997
- 1997-09-18 GR GR970402174T patent/GR3024771T3/el unknown
1998
- 1998-10-07 US US09/168,424 patent/US5962439A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US5849919A (en)	1998-12-15
KR0148389B1 (ko)	1998-11-02
US5389666A (en)	1995-02-14
CA2085844A1 (en)	1993-06-28
EP0548949A2 (de)	1993-06-30
DE69222280D1 (de)	1997-10-23
JP3419009B2 (ja)	2003-06-23
TW221291B (de)	1994-02-21
DK0548949T3 (da)	1998-03-30
ES2108076T3 (es)	1997-12-16
JPH07145057A (ja)	1995-06-06
EP0548949A3 (en)	1993-10-06
DE69222280T2 (de)	1998-03-05
DK0548949T5 (da)	1998-11-23
GR3024771T3 (en)	1997-12-31
US5589496A (en)	1996-12-31
EP0548949B1 (de)	1997-09-17
US5962439A (en)	1999-10-05

Legal Events

Date	Code	Title	Description
1998-03-15	UEP	Publication of translation of european patent specification
2004-09-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE69222280D1 (de)	1997-10-23	Kondensierte Benzeoxyessigsäurederivate
PH25550A (en)	1991-08-08	Phenylpyrazolecarboxylic acid derivatives, their use as plant-growth regulators, safeners
IL110703A0 (en)	1994-11-11	Intermediates to 4-benzoyl isoxazole derivatives
DK0850926T3 (da)	2003-02-17	Difluorprostaglandinderivater og deres anvendelse
EP0610958A3 (de)	1995-03-22	Zwischenprodukte für die Herstellung von Derivaten der 4-Oxochinolin-3-carbonsäure.
ES2103989T3 (es)	1997-10-01	Derivados de acido fenoxiacetico y composiciones farmaceuticas que los contienen.
OA09391A (en)	1992-09-15	"Isoxazole derivatives".
EP0542203A3 (en)	1993-07-14	Fused benzeneoxyacetic acid derivatives as pgl2 receptor agonists
MX9606305A (es)	1997-06-28	Productos de proteccion de cultivos.
NZ334701A (en)	2001-01-26	Dihydropyrones and use in treating retrovirus infections and diseases
FI881104A0 (fi)	1988-03-09	Menetelmä antidiabeettisina aineina käytettävien bentsoksatsiinijohdannaisten valmistamiseksi
DK0451538T3 (da)	1996-06-17	Anvendelse af pyridoindolderivater til behandling af iskæmiske lidelser
NO911149L (no)	1991-09-23	Fremgangsmaate for fremstilling av merkaptan- og merkaptoacyl-derivater.
ATE124259T1 (de)	1995-07-15	Thiazolidine-2,4-dione für die behandlung der hypertonie.
ATE71364T1 (de)	1992-01-15	Fluor enthaltende vitamin-d2-derivate.